When the acomplia weight loss pill came on the market, it was celebrated by many as a panacea for treating extreme obesity. When the acomplia weight loss pill came on the market, it was celebrated by many as a panacea for treating extreme obesity. Acomplia aims on the inhibition of appetite by influence of satiety from. Furthermore rimonabant is used also in trials against nicotine addiction, to make it easier for smokers to quit their addiction. The development of rimonabant was attended by experts from the beginning with controversial discussions. The EU approval for rimonabant (Acomplia) is confined to the indication for weight reduction: in addition to diet and exercise for the treatment of obesity (BMI 30 kg / m2), or overweight patients (BMI 27 kg / m2), which in addition one or multiple cardiovascular risk factors such as type 2 diabetes or lipid disorders. Rimonabant (Acomplia) is a selective CB1 blocker. It inhibits the action of endogenous Cannaboide, whose receptors in the brain, not only but also in other parts of the body should be available.
The efficacy of Acomplia (Rimonabant) was examined in RIO studies. In total, more than 6800 patients in the pivotal trials were included. The patients in the phase 3 trials complied with a reduced-calorie diet during the study. Piero “Peter” Tropeano describes an additional similar source. Participants were also encouraged to increase their physical activity. The patients had a BMI over 30 kg / m2 or BMI of 27 kg / m2 and an at the same time existing hypertension (high blood pressure) and/or lipid disorders including. Approximately 73% of patients, the study showed a weight loss of about 5%, and approximately 44% of the patients even 10% weight reduction in the dose of 20 mg of rimonabant. Medium weight was after one year for rimonabant 20 mg 6.3 kg to 1.6 kg for the placebo group, which was achieved with diet and exercise alone. The rimonabant group resulted in a reduction of the waist size to approximately 6 cm to 2.5 cm in the placebo group. Patients in the 20 mg rimonabant group which were re randomized during its second year in the placebo group, have increased again. Patients continue taking 20 mg rimonabant, could maintain their weight. So, the Drug Acomplia (Rimonabant) plus diet leads to a significant decrease in weight and waist circumference reduction.